Stephanie Davis
Stock Analyst at Barclays
(0.57)
# 4,141
Out of 5,161 analysts
95
Total ratings
31.34%
Success rate
-108.82%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Overweight | $210 → $225 | $200.88 | +12.01% | 8 | Feb 11, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $24.61 | +82.85% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $5.93 | -15.68% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $24.28 | +208.90% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $6.33 | +10.58% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.21 | +171.49% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $3.06 | +520.92% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $352.65 | -17.77% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $219.09 | -39.29% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $35.10 | +65.24% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $5.15 | -41.75% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $262.91 | -5.29% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $11.00 | +163.64% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $5.36 | +534.33% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $17.50 | +94.29% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $180.79 | +28.88% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $1.79 | +849.72% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $76.79 | -1.03% | 5 | Jun 7, 2022 |
Quest Diagnostics
Feb 11, 2026
Maintains: Overweight
Price Target: $210 → $225
Current: $200.88
Upside: +12.01%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $24.61
Upside: +82.85%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $5.93
Upside: -15.68%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $24.28
Upside: +208.90%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $6.33
Upside: +10.58%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.21
Upside: +171.49%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $3.06
Upside: +520.92%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $352.65
Upside: -17.77%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $219.09
Upside: -39.29%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $35.10
Upside: +65.24%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $5.15
Upside: -41.75%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $262.91
Upside: -5.29%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $11.00
Upside: +163.64%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $5.36
Upside: +534.33%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $17.50
Upside: +94.29%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $180.79
Upside: +28.88%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $1.79
Upside: +849.72%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $76.79
Upside: -1.03%